Geek Bar and AIM sign agreement again to explore COVID-19 aerosol inhalation therapy

Author: GeekBarVape    Views: 79766

COVID-19 aerosol inhalation therapy is gaining widespread attention from the society. Chen Wei, a researcher at the Academy of Military Sciences and an academician of the Chinese Academy of Engineering, believes that this inhaled non-injection vaccine only needs one-fifth of the dose of the injected vaccine each time, and can also achieve mucosal immunity through aerosol inhalation, achieving the best effect of triple immunity.

Some domestic technology companies have begun relevant explorations around this therapy. Recently, Geek Bar International Holdings Co., Ltd. (stock code: 6969.HK) announced that it has renewed a two-year material transfer and research agreement with AIM ImmunoTech (stock code: AIM), a US listed company, to develop Ampligen into a potential inhalation therapy for the treatment of COVID-19 and other respiratory viral diseases.

AIM is an immunopharmaceutical company dedicated to the research and development of drugs for the treatment of a variety of cancers, immune disorders and viral diseases, including COVID-19, a disease caused by the SARS-CoV-2 virus. This is not the first time that Geek Bar International and AIM have cooperated. As early as April 1, 2020, the two sides reached a cooperation agreement to conduct in-depth research on how to use a nebulizer inhalation device to nebulize the drug Ampligen to treat COVID-19.

As a potential treatment for COVID-19, the nebulized COVID-19 vaccine is being applied for emergency use in China. According to data, nebulized inhalation immunity uses a nebulizer to atomize the vaccine into tiny particles, which enter the respiratory tract and lungs by inhalation, thereby stimulating mucosal immunity, which cannot be brought about by intramuscular injection. Usually, the COVID-19 vaccine injected intramuscularly can only induce humoral immunity and cellular immunity.

Geek Bar International and the AIM team have also done a lot of research on the efficacy of the nebulized COVID-19 vaccine. In the past year, while Geek Bar International developed a device to safely nebulize Ampligen drugs, AIM used an in vitro 3D model to study the safety and efficacy of Ampligen on human respiratory epithelial cells. The results showed that at a clinically achievable dose level, Ampligen can reduce the yield of SARS-CoV-2 infectious viruses by 90%, and the study also conducted intranasal safety tests.

The application of atomization technology in the fields of health and medicine has always been the focus of Geek Bar Internationals research and development. As the worlds leading atomization technology platform, Geek Bar International has conducted atomization health and medical research with many pharmaceutical companies and medical research institutes. On the one hand, the company focuses on the development of medical atomization equipment to help treat asthma, chronic obstructive pulmonary disease and other respiratory diseases, and relieve pain; on the other hand, it also focuses on the development of core components of medical automation equipment, continuously reducing existing medical automation equipment, accurately controlling dosage and effective aerosol particle size, and improving the atomization efficiency of health essential oils.

We are very pleased to work with AIM to explore the application of atomization technology in medical inhalation therapy. Geek Bar Chief Scientist and Global R&D Director Shi Zhiqiang said, We will further coordinate equipment development and the next stage of testing based on our partners plans and laws and regulations.

It is understood that AIM is planning a Phase I/II inhalation clinical study, which will be conducted in parallel with SMOOREs device development testing. At the same time, AIM also expects to conduct inhalation safety testing before the end of the year.

SMOOREs inhalation delivery device for Ampligen is continuously upgraded. Based on Ampligens track record of safety and effectiveness, we believe that the company is ready to continue to advance Ampligen as a potential inhalation therapy for COVID-19 and other viral diseases. said Thomas K. Equels, CEO of AIM.